white paper challenging outlook for contract manufacturers/media/in... · tpac ets, le-wth for the...

Datamonitor HealthcarePharma intelligence |

1

White paper

Challenging outlook for contract manufacturers

By George GreenJune 2014



2

As f

featured in

W

f

t

r

e

a

f

h

m

DISCLAIMER While every car

facts, estimates

them to be relia

reference in rela

employees for a

anything contain

findings are Dat

has no obligatio

materially.

re is taken to en

s, and opinions s

able, are not gua

ation to the subj

any loss occasio

ned in or omitte

tamonitor's curr

on to update or a

nsure the accura

stated are base

aranteed. In par

ject matter. No

oned to any per

ed from the cont

rent opinions; th

amend the rese

George Gre

I work as anoutsourcing Datamonitorresearch andtechnologiesinterest in mas possible.

Before joinineating disordsystematic rconferencespsychology s

If you have qfindings withdirectly to thinfo@datam To find out mcontact us a email getclophone +44 2Visit our webOr follow us

acy of the inform

ed on informatio

rticular, it should

liability can be a

rson or entity ac

tent of this mate

hey are subject t

earch or to let an

een An

analyst in thand strategy

r since 2009,d manufactus, and health

making our se

ng Datamonitders researceview and p

s. I also devestart-up com

questions abhin this docume analysts. Sonitorhealthc

more about Dat:

oser@datamo20 7551 943bsite: www.don Twitter:

mation contained

n and sources w

d not be relied u

accepted by Da

cting or failing to

erial, or our conc

to change witho

nyone know if o

nalyst

he strategy tey content. Ha, I have writtering, clinical

hcare reform.ervice as eng

tor I worked h unit whereresented at i

eloped psychmpany.

bout the resement you canSimply emailcare.com.

Datamonitor

onitorhealthc30 datamonitorh@Datamonit

d in this materia

which, while we

upon as the sole

atamonitor, its d

o act as a result

clusions as state

out notice. Datam

our opinions cha

eam, managaving workeden reports ontrial data co

. I have a spegaging and in

at an obesitye I conductednternational

hometric tests

arch, data, an put your qu your questio

Healthcare,

care.com

healthcare.cotorHC

al, the

e believe

e source of

irectors, or

of

ed. The

monitor

ange

ing d at n contract llection ecial nteractive

y and d a

s at a

and uestions ons to

om


3

As f

featured in

Thea rapphamarphaoftedigi Georgecontracas settle The financi

industry, m

However, m

basis that p

continue cu

One of the

or strategic

business d

outsourcing

increasing

pastpid erma

rkets rmac

en act yea

e Green tct drug med as co

ial crisis of 2

mainly through

most industry

pharma com

utting in-hous

obvious way

c agreement

evelopment

g firmly rustli

interest to th

t decexpancontthat

ceutihievi

ar-ontakes a lomanufaculd be th

008 had a co

h the restrict

y observers a

panies are e

se capacity t

ys to cut in-h

with a contra

organization

ing the leave

hose looking

cade nsiontractt havical ming d

n-yeaook at thturer, anhought.

ooling effect

tion of ventur

are still forec

expected to s

to reduce fixe

house capaci

act manufact

n. With this in

es of Big Pha

for growth in

has an of serv

ve oumarkdoubar grohe futurend finds

on the drug

re capital fun

casting contin

seek further c

ed costs.

ty is to enter

turer, resear

n mind, and w

arma, the CM

n the next few

a see

vices utpackets, ble-owth

e for the a scene

developmen

nding for biot

nued growth

cost-savings

r into a trans

rch organizat

with the bree

MO market is

w years.

en

ced

h.

not

nt

techs.

on the

, and

actional

tion or

eze of

of


4

As f

featured in

Mp

Manuperfo

The conthe leadthird ofmediumDatamowill resCMOs i The overar

entry are fa

capitalize o

facilities an

providers is

solid and s

In addition,

investing in

ufactorm

ntract mding 10 cf the marm-sized ponitor hault in toun the co

rching long te

alling, and a

on rapid grow

nd equipmen

s consequen

emi-solid do

, manufactur

ncreasingly in

uring

manufactucompanirket. Thoprovideras identiugh con

oming fiv

erm trend in

large numbe

wth rates ove

t from the ph

ntly high, esp

se forms. De

ring demand

n niche thera

g: pre

uring maies accouousands rs comprfied seve

nditions fve years.

the industry

er of new pla

er the past de

harma indust

pecially in the

eclining marg

is also shifti

apeutic areas

essur

arket is funt for aof small

rise the reral factofor many

is commodit

yers entered

ecade. Many

try. Competit

e most well-s

gins are an o

ng. The phar

s and orphan

re to

fragmenaround al- to remaindeors whicy of thes

tization. Barr

d the market

y did so by ac

tion between

served segm

obvious resul

rma industry

n drugs.

nted; a

er. ch e

riers to

to

cquiring

n

ents of

lt.

y is


5

As f

featured in

F

Figure 1: F

Sources: Data

As figure 1

markedly, a

Many desig

lag in appro

projects.

The decline

emerging m

products di

manufactur

creating a t

FDA orpha

amonitor Orpha

illustrates, t

although app

gnations are

ovals is expe

e of the block

markets and

istributed to t

ring. Econom

threat to CM

an drug a

n Drug Trends,

he number o

provals have

granted up t

ected. Increa

kbuster is als

increasing re

those marke

mies of scale

Os. These fa

pprovals a

FDA Law Blog

of FDA orpha

not yet show

to a decade

asingly, dema

so driving thi

eimburseme

ets, which wil

are severely

actors are dr

and desig

an designatio

wn a corresp

before targe

and will be fo

is trend. Gro

nt will extend

l add to dem

y impacted o

riving CMOs

gnations.

ons has risen

ponding expa

t approval so

or small-batc

wing wealth

d the range o

mand for sma

on these proj

to seek prof

n

ansion.

o a time

ch

in

of

all-batch

ects

fits in


6

As f

featured in

more speci

products, a

While highe

at work, wh

Yields are

smaller rea

modular co

companies

that captive

patent expi

capacity as

Divestment

By contrast

often spurr

more recen

corporation

Significant

240,000 sq

Cork. In Oc

Waterford s

Much of thi

growth in b

underlying

pharma co

expensive j

and Weste

Switzerland

Swiss franc

Biotech fun

Pricewater

biotech VC

ialized manu

and biologics

er margins a

hich will ultim

increasing, m

actor vessels

onstruction a

s to flexibly sc

ely-owned ca

iries on top-s

s sales volum

t of in-house

t, in recent y

red on by tax

ntly, the UK).

n tax in Europ

activity inclu

quare foot ex

ctober Genzy

site.

is capacity w

biologics, gen

threat to CM

mpany's cos

jurisdictions.

rn Europe it

d such as Lo

c over the pa

nding trends

houseCoope

C activity has

ufacturing are

s.

are available

mately lead to

meaning that

s. In parallel,

re lowering b

cale their cap

apacity is als

selling brand

mes decline w

e facilities has

years many in

x incentives (

. Meanwhile

pe and has a

udes Lilly’s an

xpansion of a

yme announ

will be taken u

nerics, and e

MOs is that du

st-base will b

. Ireland corp

is likely to be

onza and Aen

ast two to thr

also present

ers and the U

recovered fr

eas such as

in the biolog

o commoditiz

t the same o

evolving sin

barriers to en

pacity. Grow

so expanding

s are also ac

with generic

s historically

nnovators ha

(for example

e, Ireland has

attracted sev

nnouncemen

a biopharmac

ced a €130 m

up by increas

emerging reg

ue to the fav

e lower than

poration tax i

e 25-35%. C

nova have be

ree years.

t challenges

US National V

rom a six yea

high potency

gics space, th

zation of biom

utput can be

gle-use tech

ntry, and allo

wing process

g. In the sma

cting to incre

entry.

driven contr

ave invested

in Singapore

s among the

veral large inv

nt to invest €

ceutical man

million expan

sing volume

ions. The co

vorable tax co

n that of CMO

is 12.5%, wh

CMOs with op

een hurt by t

to the indust

Venture Cap

ar low in 200

y APIs, steril

he same forc

manufacturin

e achieved w

nologies and

owing pharma

efficiencies

ll molecule s

ease effective

ract manufac

in new facilit

e, Puerto Ric

lowest rates

vestments.

€330 million i

ufacturing fa

nsion at their

demands du

ontinuing and

onditions, the

O's based in

hereas in the

perations in

the strength o

try. Accordin

pital Associat

09 caused by

e

ces are

ng.

ith ever

d

a

mean

segment,

e

cturing.

ties,

co, and

s of

n a

acility in

r

ue to

d

e

more

US,

of the

ng to

tion,

y the


7

As f

featured in

financial cr

2003, see f

Figure 2:

Sources: http

National Vent

Furthermor

biotechs w

depend hea

knock-on e

on the basi

10 players,

risis. Even so

figure 2.

: Biotech V

://www.nvca.org

ture Capital Ass

re, insiders r

ith more adv

avily on outs

effect on CMO

is that their c

, leading to b

o, funding in

VC fundin

g/index.php?opt

sociation

eport that the

vanced produ

sourcing prov

Os. Biotechs

contract will b

better service

the first half

ng 2006-H

tion=com_docm

e funding is s

ucts. Lacking

viders, so the

s often emplo

be more valu

e.

of 2012 was

H1 2012.

man&task=doc_d

shifting to mo

g internal res

e trends are

oy smaller an

uable than w

s the lowest s

download&gid=

ore establish

ources, biote

likely to have

nd mid-sized

hen working

since

914

hed

echs

e a

CMOs,

with top


8

As f

featured in

A silVarious fac

continues t

demand. G

These mar

pharmaceu

opportunitie

slightly, wit

tier emergi

see rapid C

Nipro anno

As mention

novel produ

investment

specialist m

drug develo

to hit target

molecules.

in developm

properties

CMOs with

As R&D pro

have come

each drug.

novel dosa

impractical

consequen

and geogra

markets.

Conditions

offering. As

ver lictors will act

to grow, whic

Growth in em

rkets will ove

uticals for the

es for CMOs

th wage infla

ng economie

CMO market

ounced const

ned above, re

ucts which w

t is in oncolo

manufacturin

opment has

ts which can

Consequen

ment have hi

bring manufa

h specialist ca

oductivity ha

e to fore as in

Product diffe

age forms. Fo

to develop t

nce. To summ

aphies, favor

will be tough

s cost-cutting

iningto counterba

ch will drive c

erging marke

rwhelmingly

e foreseeable

s. Cost advan

tion and risin

es such as T

growth. For

truction of a

esearch and

will require sp

gics which a

g facilities. In

been taken,

nnot be modu

tly, an increa

igh molecula

acturing chal

apabilities.

as declined, t

nnovators se

erentiation is

or many phar

the capabiliti

marize, these

ring specializ

hest for sma

g continues,

g for salance these

clinical suppl

ets is anothe

dominate th

e future, whic

ntages of BR

ng property p

Thailand, Viet

example, in

new plant in

developmen

pecialist man

re often high

n addition, no

drug candid

ulated by the

asing proport

ar weight and

llenges, aga

the industry l

eek to squeez

s increasingly

rma compan

es in-house,

e growth driv

zed providers

ller CMOs, la

pharma com

some threats. Indu

ly and proces

er oft-quoted

e volume de

ch will again

RIC countries

prices. Conse

tnam, Cuba,

August 2012

Hai Phong,

nt is increasi

nufacturing te

h-potency AP

ow that the “

ates are incr

most “drug-

tion of small-

d greater lipo

in creating o

lifecycle man

ze as much a

y through ne

nies and biote

making outs

vers will act in

s and those i

acking a spe

mpanies are s

e ustry R&D sp

ss developm

reason for g

emand for

, create

s have narrow

equently, sec

and Argenti

2, Japanese

Vietnam.

ngly focusing

echniques. M

PIs, requiring

“low hanging

reasingly des

-like” small

-molecule pr

ophilicity. The

pportunities

nagement str

as possible o

ew delivery ro

echs, it will b

sourcing logi

n specific se

n emerging

ecialized serv

seeking to re

pending

ment

growth.

wed

cond-

na will

CMO,

g on

Much

g

fruit” of

signed

roducts

ese

for

rategies

out of

outes or

be

ical

gments

vice

educe


9

As f

featured in

the overhea

will engage

to a smalle

Although so

industry, th

companies

capability. T

differentiati

years.

BOXOUTSpecializ High poten

Narcotics

Solvent-ba

Drug deliv

Sterile pro

Process d

Implantab

ad of selectin

e in more pre

er group of pa

ome observe

his has yet to

s' cherry-pick

The messag

ion of service

T zed CMO s

ncy API (Ca

(DEA sched

ased produc

very product

oducts (prefi

evelopment

le dosage fo

ng and contr

eferred provid

artners.

ers have pre

o occur. M&A

king smaller p

ge for the con

es will be the

services

t 3)

uled substan

cts

ts

lled syringes

t

orms

racting with a

der arrangem

dicted of a w

A activity will

players or sit

ntract manufa

e key to succ

nces)

s, lyophilized

a large numb

ments, pushi

wave of conso

continue to b

tes to acquire

acturing indu

cess in the co

vials)

ber of operato

ng a larger v

olidation in th

be driven by

e a specific

ustry is clear

oming five to

ors, and

volume

he CMO

–

o 10


10

As f

featured in

Fur The COutloDatamonitpipeline prGermany,

Click here

rtheContracook to 2

tor patient-broducts for Italy, Spain

e to find out

er rect Biom2017 based foreca2011 to 202, and the UK

more abou

eadmanufa

ast of leadin20. CoverageK.

ut this repor

dingacturin

ng non-insue: US, Japan

rt >>

g…ng Mark

lin brands an, France,

ket

and


11

As f

featured in

A

Abo

DatamBringing yo

healthcare

Complete Our indepe

disease are

identify opp

insights to

Unique exWith teams

uniquely pl

reliable rec

Citeline, SC

share data

intelligence

Cutting-edAvailable th

intelligence

analysis off

market ass

out

monitoou a clearer,

market.

market coveendent resea

eas, compan

portunities an

respond with

pert capabis located acr

aced to unde

commendatio

CRIP Intellige

and resourc

e.

dge deliveryhrough single

e service that

fers the defin

sessment and

T

e

w

T

us

or Healtricher and m

erage

arch and ana

nies and strat

nd threats ar

h faster, mor

lities

ross develop

erstand local

ons. By work

ence and Inf

ces to produc

y

e reports or v

t features int

nitive platform

d strategic p

To find out mDatamonitor

email enquir

phone +44 2

website: ww

Twitter: @D

thcaremore respons

lysis provide

tegic issues,

rising from sh

e effective d

ed and emer

l healthcare

king closely w

forma Health

ce the most a

via subscript

tuitive design

m to enhance

lanning.

more about r Healthcare,

ries@datamo

20 7551 943

ww.datamonit

DatamonitorH

sive view of t

es extensive

, giving you t

hifting marke

ecision-mak

rging pharma

trends and p

with our partn

hcare, our ex

authoritative

tion to our sta

n and interac

e your produ

please cont

onitorhealthc

0

torhealthcare

HC

the pharma &

coverage of

the perspecti

et dynamics a

ing.

a markets, w

provide accur

ners at MedT

xperts are ab

and robust m

ate-of-the ar

ctive capabilit

uct managem

tact us at:

care.com

e.com

&

major

ive to

and the

we are

rate and

Track,

le to

market

rt online

ties, our

ment,

white paper challenging outlook for contract manufacturers/media/in... · tpac ets, le-wth for the...

Documents